Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

By: Investing.com

Sep 19 2024
8
299 Views

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones — Psyence Group's NASDAQ-Listed

Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care
Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorde… [+9035 chars]

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Prediction of antimicrobial resistance of Klebsiella pneumoniae from genomic data through machine learning

Howard W. Robin Sells 14,881 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule

Warning: September Asthma Spike Ahead

Brokerages Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $1.50

PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

Share this page

Guest Posts by Easy Branches

Feadship unveils first details of new 75m electric

Cantieri di Pisa announces €27 million order book

Discover the New Pearl 82 - The Most Compact Super

Francis Lapp – Personality of the Year

all our websites

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Related

Share this page